EXPERTISE
Molecule Rescue & Repositioning
Reviving stalled or underperforming assets by identifying root causes and redesigning formulation, delivery, and development strategy to enable clinically viable exposure and progression.
Unlocking value from molecules that failed due to formulation, variability, or exposure limitations — transforming them into viable clinical candidates.
The Challenge
- Many promising molecules fail due to poor bioavailability, instability, or inconsistent exposure
- Variability in pharmacokinetics often leads to unreliable clinical outcomes
- Early formulation and development decisions may not align with clinical exposure requirements
- As a result, assets are often deprioritised despite strong underlying pharmacology
The Challenge
- Early-stage molecules often lack the physicochemical stability required for downstream development
- Poor solid-state characteristics can compromise manufacturability and scalability
- Limited early characterisation leads to late-stage failures and reformulation cycles
How We Rescue and Reposition Molecules
Root-Cause Failure Analysis
Systematically identifying whether limitations arise from solubility, permeability, stability, or pharmacokinetic behaviour
PK & Exposure Re-Alignment
Aligning formulation performance with clinically relevant exposure targets using modelling and experimental insights
Formulation & Delivery Redesign
Re-engineering delivery systems to improve exposure, stability, and consistency
Development Strategy Repositioning
Redefining dosing strategies, clinical pathways, or positioning to maximise probability of success
Where We Deliver Impact
Variability Reduction
Stabilising inconsistent exposure profiles to enable reliable therapeutic performance
Stability & Formulation Rescue
Addressing degradation, instability, and formulation limitations that prevent progression
Exposure Re-Engineering
Transforming poorly bioavailable molecules into clinically viable candidates
Reformulation and delivery optimisation revived a molecule previously limited by variability and instability, enabling consistent exposure and clinical progression.
Outcomes
- Recovery of clinically viable exposure profiles
- Reduced variability and improved consistency in pharmacokinetics
- Enhanced formulation robustness and stability
- Re-enablement of stalled assets for clinical progression
- Extension of asset lifecycle and commercial value
WHERE THIS FITS IN DEVELOPMENT
Applied across preclinical and clinical stages to rescue stalled or underperforming assets by improving exposure, reducing variability, and enabling progression into clinical evaluation.
Have a molecule that didn’t meet expectations?
Partner with Dhee Lifesciences to identify root causes, redesign development strategy, and unlock its true therapeutic potential.
